Association between pan-immune-inflammation value and no-reflow in patients with ST elevation myocardial infarction undergoing percutaneous coronary intervention

References

• GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329(22):1615–1622.
   PubMed Web of Science ®Google Scholar
• Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361(9351):13–20. doi: 10.1016/S0140-6736(03)12113-7.
   PubMed Web of Science ®Google Scholar
• Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv. 2008;72(7):950–957. doi: 10.1002/ccd.21715.
   PubMed Web of Science ®Google Scholar
• Su Q, Ye Z, Sun Y, et al. Relationship between circulating miRNA-30e and no-reflow phenomenon in STEMI patients undergoing primary coronary intervention. Scand J Clin Lab Invest. 2018;78(4):318–324. doi: 10.1080/00365513.2018.1467571.
   PubMed Web of Science ®Google Scholar
• Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of ‘no-reflow’ after percutaneous coronary intervention. Circulation. 1994;89(6):2514–2518. doi: 10.1161/01.cir.89.6.2514.
   PubMed Web of Science ®Google Scholar
• Sabin P, Koshy AG, Gupta PN, et al. Predictors of no- reflow during primary angioplasty for acute myocardial infarction, from medical college hospital, Trivandrum. Indian Heart J. 2017;69 Suppl 1(Suppl 1):S34–S45. doi: 10.1016/j.ihj.2016.12.012.
   PubMedGoogle Scholar
• Namazi M, Mahmoudi E, Safi M, et al. The no-reflow phenomenon: ıs it predictable by demographic factors and routine laboratory data? Acta Biomed. 2021;92(5):e2021297.
   PubMedGoogle Scholar
• Rostami A, Tajlil A, Separham A, et al. Association between neutrophil-to-Lymphocyte ratio and the systemic ınflammatory ımmunologic ındex and the angiographic SYNTAX score and the TIMI flow grade in acute STEMI: a cohort study. J Tehran Heart Cent. 2021;16(4):147–155.
   PubMedGoogle Scholar
• Esenboğa K, Kurtul A, Yamantürk YY, et al. Systemic immune-inflammation index predicts no-reflow phenomenon after primary percutaneous coronary intervention. Acta Cardiol. 2022;77(1):59–65. doi: 10.1080/00015385.2021.1884786.
   PubMed Web of Science ®Google Scholar
• Kelesoglu S, Yilmaz Y, Elcik D, et al. Increased serum systemic Immune-Inflammation ındex is ındependently associated With severity of carotid artery stenosis. Angiology. 2023;74(8):790–797. doi: 10.1177/00033197221144934.
   PubMed Web of Science ®Google Scholar
• Fucà G, Guarini V, Antoniotti C, et al. The pan-ımmune-ınflammation value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the valentino and TRIBE first-line trials. Br J Cancer. 2020;123(3):403–409. doi: 10.1038/s41416-020-0894-7.
   PubMed Web of Science ®Google Scholar
• Group TS. The thrombolysis in myocardial ınfarction (TIMI) trial. Phase I findings. N Engl J Med. 1985;312(14):932–936.
   PubMed Web of Science ®Google Scholar
• Gibson CM, de Lemos JA, Murphy SA, et al. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation. 2001;103(21):2550–2554. doi: 10.1161/01.cir.103.21.2550.
   PubMed Web of Science ®Google Scholar
• Gibson CM, Cannon CP, Murphy SA, et al. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation. 2002;105(16):1909–1913. doi: 10.1161/01.cir.0000014683.52177.b5.
   PubMed Web of Science ®Google Scholar
• Niccoli G, Burzotta F, Galiuto L, et al. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009;54(4):281–292. doi: 10.1016/j.jacc.2009.03.054.
   PubMed Web of Science ®Google Scholar
• Lin F, Zhang LP, Xie SY, et al. Pan-ımmune-ınflammation value: a new prognostic ındex in operative breast cancer. Front Oncol. 2022;12:830138. doi: 10.3389/fonc.2022.830138.
   PubMed Web of Science ®Google Scholar
• Ligorio F, Fucà G, Zattarin E, et al. The pan-ımmune-ınflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab. Cancers (Basel). 2021;13(8):1964. doi: 10.3390/cancers13081964.
   PubMed Web of Science ®Google Scholar
• Jaffe R, Charron T, Puley G, et al. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation. 2008;117(24):3152–3156. doi: 10.1161/CIRCULATIONAHA.107.742312.
   PubMed Web of Science ®Google Scholar
• Galasso G, Schiekofer S, D'Anna C, et al. No-reflow phenomenon: pathophysiology, diagnosis, prevention, and treatment. A review of the current literature and future perspectives. Angiology. 2014;65(3):180–189. doi: 10.1177/0003319712474336.
   PubMed Web of Science ®Google Scholar
• Ito H. No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat Rev Cardiol. 2006;3(9):499–506. doi: 10.1038/ncpcardio0632.
   Web of Science ®Google Scholar
• Striz I, Brabcova E, Kolesar L, et al. Cytokine networking of innate immunity cells: a potential target of therapy. Clin Sci. 2014;126(9):593–612. doi: 10.1042/CS20130497.
   Web of Science ®Google Scholar
• Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13(1):34–45. doi: 10.1038/nri3345.
   PubMed Web of Science ®Google Scholar
• Kurtul A, Yarlioglues M, Murat SN, et al. Usefulness of the platelet-to-lymphocyte ratio in predicting angiographic reflow after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. Am J Cardiol. 2014;114(3):342–347. doi: 10.1016/j.amjcard.2014.04.045.
   PubMed Web of Science ®Google Scholar
• Yildiz A, Yuksel M, Oylumlu M, et al. The utility of the platelet-Lymphocyte ratio for predicting no reflow in patients with ST-segment elevation myocardial ınfarction. Clin Appl Thromb Hemost. 2015;21(3):223–228. doi: 10.1177/1076029613519851.
   PubMed Web of Science ®Google Scholar
• Vakili H, Shirazi M, Charkhkar M, et al. Correlation of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio with thrombolysis in myocardial infarction frame count in ST-segment elevation myocardial infarction. Eur J Clin Invest. 2017;47(4):322–327. doi: 10.1111/eci.12736.
   PubMed Web of Science ®Google Scholar
• Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212–6222. doi: 10.1158/1078-0432.CCR-14-0442.
   PubMed Web of Science ®Google Scholar
• Yang R, Chang Q, Meng X, et al. Prognostic value of systemic immune-inflammation index in cancer: a meta-analysis. J Cancer. 2018;9(18):3295–3302. doi: 10.7150/jca.25691.
   PubMed Web of Science ®Google Scholar
• Yaşar E, Bayramoğlu A. Systemic ımmune-ınflammation ındex as a predictor of microvascular dysfunction in patients with cardiac syndrome X. Angiology. 2022;73(7):615–621. doi: 10.1177/00033197221087777.
   PubMed Web of Science ®Google Scholar
• Tang Y, Zeng X, Feng Y, et al. Association of systemic Immune-Inflammation ındex With Short-Term mortality of congestive heart failure: a retrospective cohort study. Front Cardiovasc Med. 2021;8:753133. doi: 10.3389/fcvm.2021.753133.
   PubMed Web of Science ®Google Scholar
• Gok M, Kurtul A. A novel marker for predicting severity of acute pulmonary embolism: systemic immune-inflammation index. Scand Cardiovasc J. 2021;55(2):91–96. doi: 10.1080/14017431.2020.1846774.
   PubMed Web of Science ®Google Scholar